Table 1.

Participant Age, Menopausal Symptoms, and Cognitive Assessment

	17β-Estradiol
	placebo (n = 21)				1 mg (n = 21)				2 mg (n = 33)
	Mean	SD	Min.	Max.	Mean	SD	Min.	Max.	Mean	SD	Min.	Max.	One-way ANOVA (E2 Groups)
Age	56.76	2.62	52.00	60.00	55.52	2.56	51.00	59.00	61.85	6.37	53.00	74.00	F (2, 72) = 12.58, p < 0.001
MSC	19.29	10.18	6.00	49.00	15.71	9.00	4.00	37.00	14.72	9.61	1.00	41.00	F (2,72) = 1.49, p = 0.23
DRS	141.24	2.12	137.00	144.00	141.24	1.92	137.00	144.00	139.97	8.90	92.00	144.00	F (2,72) = 0.39, p = 0.67
GDS	1.52	0.51	1.00	2.00	1.48	0.51	1.00	2.00	1.73	0.45	1.00	2.00	F (2,72) = 2.07, p = 0.13
BCRS	9.14	1.20	7.00	11.00	9.29	1.45	8.00	13.00	9.55	1.23	8.00	12.00	F (2,72) = 0.68, p = 0.51
MMSE	28.90	1.41	26.00	30.00	29.10	1.04	26.00	30.00	29.27	0.98	26.00	30.00	F (2,72) = 0.67, p = 0.51

Comparison across the three treatment groups (placebo, 1 mg, and 2 mg) for age, menopausal symptoms (MSC = Menopause Symptom Checklist total score) and cognitive assessments (DRS = Mattis Dementia Rating Scale 2; GDS = Global Deterioration Scale; BCRS = Brief Cognitive Rating Scale; MMSE = Mini Mental State Exam). Differences in scores for the treatment groups were assessed using one-way ANOVA; the only significant (α = 0.05) difference between groups was in age.